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Background: Epidemiological studies indicate that the use of artificial sweeteners doubles the risk for 48	
Crohn’s Disease (CD). Herein, we experimentally quantified the impact of 6-week supplementation with a 49	
commercial sweetener (Splenda®; ingredients sucralose maltodextrin, 1:99, w/w;) on both the severity of CD-50	
like ileitis and the intestinal microbiome alterations using SAMP1/YitFc (SAMP) mice. 51	
Methods: Metagenomic shotgun DNA sequencing was first used to characterize the microbiome of ileitis-52	
prone SAMP mice. Then, 16S rRNA microbiome sequencing, qPCR, fluorescent in situ hybridization (FISH), 53	
bacterial culture, stereomicroscopy, histology and myeloperoxidase (MPO) activity analyses were then 54	
implemented to compare the microbiome and ileitis phenotype in SAMP with that of control ileitis-free AKR/J 55	
mice after Splenda supplementation. 56	
Results: Metagenomics indicated that SAMP mice have a gut microbial phenotype rich in Bacteroidetes, and 57	
experiments showed that Helicobacteraceae did not have an exacerbating effect on ileitis. Splenda did not 58	
increase the severity of (stereomicroscopic/histological) ileitis; however, biochemically, ileal MPO activity 59	
was increased in SAMP treated with Splenda compared to non-supplemented mice (P<0.022), and healthy 60	
AKR mice. Splenda promoted dysbiosis with expansion of Proteobacteria in all mice, and E. coli overgrowth 61	
with increased bacterial infiltration into the ileal lamina propria of SAMP mice. FISH showed increase malX 62	
gene carrying bacterial clusters in the ilea of supplemented SAMP (but not AKR) mice.   63	
Conclusions: Splenda promoted gut Proteobacteria, dysbiosis and biochemical MPO reactivity in an 64	
experimental model of (Bacteroidetes-rich) CD. Our results indicate that although Splenda may promote 65	
parallel microbiome alterations in CD-prone and healthy hosts, CD may possess a pro-inflammatory 66	
predisposition to exacerbated MPO antibacterial intestinal reactivity due to the consumption of sucralose-67	
maltodextrin foods, which seems unlikely to occur in individuals not affected with CD.   68	
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INTRODUCTION 69	
Recent self-assessment dietary surveys indicate that ~10% of patients suffering from inflammatory 70	
bowel disease (IBD) believe that ‘sugary foods’ worsen the severity of their symptoms and trigger flare-ups.1-71	
3 Epidemiological studies have correspondingly shown a strong association between the use of artificial 72	
sweeteners (AS) and an increased risk for IBD (odds ratio > 2.12; 95% CI, 1.1-4.2),4-6 but the mechanisms of 73	
diet-induced IBD are unknown. Although nutrition has long been considered critical to improve the patient’s 74	
malnutrition and iron deficiency in severe IBD,7, 8 aside from Delphi expert opinions and systematic reviews, 75	
there are currently no evidence-based dietary guidelines to help IBD patients managing their own diet.4 The 76	
importance of novel dietary studies to promote gut health in IBD has been independently highlighted 2 by 77	
both patients and clinicians who listed ‘diet’ among the top 10 research IBD priorities in the 2017 James Lind 78	
Alliance report.9 Conducting and interpreting dietary studies in humans is however challenging due to 79	
genetic, microbiome, and dietary variability. As alternative, animal models have been used to examine the 80	
effects of dietary ingredients, individually, on numerous diseases. Dietary habits deemed unhealthy (e.g., 81	
‘western diets’; rich in fats and sugars) are for instance believed to alter the gut microbiome and either 82	
directly or indirectly trigger IBD. Despite substantial progress in our knowledge of acute models of intestinal 83	
inflammation, the precise effect of ‘multi-ingredient’ AS on exacerbation of IBD remains unclear.  84	
The ongoing and increased prevalence of obesity, which coincides with the rise of IBD diagnoses, 85	
indicates there is a possible link between the risk factors of both diseases. Due to the growing obesity 86	
epidemic and the pressure to avoid sugar to reduce caloric intake, the food industry and consumers are 87	
using AS as substitutes for ‘table sugar’. The main ingredient of sugar is often sucrose, a disaccharide of 88	
glucose and fructose. Instead of sucrose, AS (e.g., Splenda®) use ‘sucralose’ as a non-caloric sweetening 89	
ingredient typically at 1% concentration, mixed with a filling ingredient (99%) that provides texture and 90	
volume.10 The most commonly used filler is maltodextrin, a nutritive polysaccharide regarded as inert and 91	
affirmed as GRAS (generally regarded as safe) by the US Food and Drug Administration.11 However, studies 92	
indicate that neither sucralose nor maltodextrin are biologically inert.12-17 The potential adverse effects of AS 93	
across various diseases are controversial as they vary with the diseases and human populations studied 94	
(e.g., obesity, diabetes),15 with some reports indicating mild or no negative effects.12, 17  95	
Because the dietary modulation of IBD is a realistic goal that may involve modifications in patient 96	
behavior, especially in Crohn’s Disease (CD), which is one of the IBD that has the strongest correlation with 97	
dietary habits, it is important to determine the effect of multi-ingredient commercial AS (e.g., sucralose and 98	
maltodextrin in Splenda) on IBD. The information derived from studying any commercial mixture of dietary 99	
ingredients may assist clinicians and patients in making informed and corrective dietary decisions that could 100	
potentially alleviate IBD symptoms and prevent flare-ups. Using mice, in this study, we first determined the 101	
features and variability of the gut microbiome in an spontaneous mouse model of CD-like ileitis [strain 102	
SAMP1/YitFc (SAMP)] compared to its parental ileitis-free control mouse strain AKR/J (AKR), and then we 103	
quantified the inflammatory effects of 6-week chronic supplementation of a commercial AS (Splenda) on IBD 104	
using the SAMP ileitis mouse model. The objectives of this study were i) first to characterize the fecal 105	
metagenome (i.e., the collective composition profiling of the bacterial genomes in the gut) of experimental 106	
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SAMP mice and the ability of animal cohousing in transmitting SAMP ileitis to healthy AKR mice; and then, ii) 107	
to quantify the effects of Splenda supplementation on CD-ileitis using SAMP and AKR mice, and a fecal 108	
homogenization protocol18 where all mice prior to experimentation were exposed to (via oral gavage) the 109	
pooled of fecal microbes present in all mice. As a CD-relevant morphological feature, a recent Three-110	
Dimensional (3D) Stereomicroscopic (SM) Assessment and Pattern Profiling (3D-SMAPgut) phenotyping 111	
protocol revealed that SAMP mice naturally develop segmental enteritis with cobblestone lesion formation in 112	
a fashion resembling CD (100% penetrance).18 Herein, we discovered that ileitis-prone SAMP mice have a 113	
microbiome enriched with Bacteroidetes species (as described in CD), and that the chronic ileitis phenotype 114	
is not transmissible to AKR or affected by the presence of Helicobacter in the gut as a commensal. In this 115	
microbial context, we then determined that six weeks of Splenda supplementation in the drinking water of 116	
adult inflamed mice did not worsen the morphological severity of ileitis in SAMP mice, based on histological 117	
or stereoenterotype (3D-SMAPgut) score indexes. However, Splenda did cause gut microbiota dysbiosis in 118	
both SAMP and AKR mice, with a predominant increase of Proteobacteria, and a significant increase of pro-119	
inflammatory myeloperoxidase (MPO) activity and penetrating bacteria primarily in the gut tissues of SAMP 120	
mice (ileitis). Interestingly, Splenda did not induce such increase in MPO activity or bacterial tissue 121	
abundance in healthy mice (AKR), indicating that Splenda might have pro-inflammatory implications only if 122	
consumers have susceptibility to CD, potentially aggravating the severity of symptoms and flare-ups, which 123	
would be in agreement with observations reported by IBD patients1-3. 124	
 125	
MATERIALS AND METHODS 126	
Mice and husbandry. This study was conducted with protocols approved by the Institutional Animal 127	
Care and Use Committee of Case Western Reserve University (IACUC-CWRU), using SAMP, AKR, and 128	
C57BL/6J (B6) mice, which are maintained as SPF (specific-pathogen-free) colonies at the Animal Resource 129	
Center (ARC-CWRU, Cleveland, Ohio, USA). Mice were housed in shoe box cages with pine shavings 130	
bedding, offered reverse osmosis drinking water (e.g., free of salt, bacteria, viruses), fed ad libitum irradiated 131	
standard laboratory chow (Prolab RMH 3000; porcine animal-derived fat preserved with BHA; 6.8% content 132	
by acid hydrolysis) and kept on 12-h light–dark cycles.18 Age- and sex-matched mice (5-7/group) were used 133	
in all experiments. SAMP mice originated from selective sibling breeding of AKR mice, with an outcrossing to 134	
B6, as previously described.18-20 SAMP mice are prone to develop progressive ileitis with ‘typical cobblestone 135	
lesions’ resembling the 3D features of CD.18-20 Preliminary whole genome sequencing analysis indicates that 136	
SAMP ileitis is a polygenic disease as it is CD in humans.21  As needed, AKR and B6 mice were used as 137	
parental genetic ileitis-free controls. Splenda experiments were conducted with mice produced in the main 138	
SAMP breeding colony (herein designated as Facility A). A parallel alternate colony (Facility B) was used for 139	
verification purposes of metagenomic findings in facility A. To maintain phenotypic and genetic homogeneity 140	
of SAMP in both facilities, periodic exchange of breeders occurred between the 2 facilities every 12 months.  141	
‘Breeder mice’ typically set at 1:2 male:female ratio produced offspring ‘experimental mice’ which are 142	
weaned at 3-4 weeks of age and maintained next to the ‘breeder mice’ cages. Helicobacter-negative SPF 143	
SAMP mice, re-derived as at the National Cancer Institute (Center for Cancer Research; Frederick, 144	
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Maryland, USA,), were maintained and tested on a high-level of isolation unit within the ARC-CWRU, using 145	
the husbandry standards described above.   146	
Fecal metagenomic shotgun DNA sequencing. Due to the unresolved issues associated with the 147	
metagenomic shotgun DNA sequencing analysis of all kingdoms present in the gut microbiota, which could 148	
be relevant as a cause or consequence of IBD,22, 23 herein we decided to focus primarily on bacteria, and 149	
screen only for viruses. To prevent sequencing and post-sequencing analytical variability, validated 150	
bioinformatic methods were used on sequencing raw and high-quality filtered data (i.e., Illumina and 151	
Metaphlan).24 We focused on bacteria because wholesome ‘kingdom-agnostic’ metagenomics requires 152	
controlling for large differences in cellular integrity across all members of the gut flora,22, 23 which was not 153	
widely validated or available when the study was initiated. 154	
For DNA extraction, flash-frozen fecal samples were homogenized in 1x PBS (1:5, grams:vol) with 155	
ceramic beads and mechanical disruption using Fast Prep FP120 homogenizer (setting 5 for 30 s at 4oC 156	
twice, with one freezing cycle in between). Homogenates, after a 20-second centrifugation at 10,000 x g at 157	
4oC, were shipped overnight to the laboratory of Dr. Skip Virgin at Washington University, Saint Louis, MO. 158	
DNA extraction and purification from the homogenates were performed using commercial Qiagen DNA 159	
extraction mini kit based on the manufacturer instructions. The integrity (and quantity) of the DNA was 160	
monitored by spectrophotometry and gel electrophoresis. dsDNA was quantified with an Invitrogen Qubit 161	
Fluorometer (8.62±5 µg/mL; Quant-iT). Shotgun metagenome analysis was conducted following library 162	
preparation using Illumina reagents and Miseq sequencing validated protocols. Standard Fastaq files were 163	
then used to quantify the abundance of bacterial reads using MetaPlhan alignment and analytical pipelines 164	
developed by Dr. Huttenhower at Harvard School of Public Health.24 Briefly, raw FASTQ files were 165	
transferred to a local server where Metaphlan pipelines were run on Galaxy where the R1 and R2 fasta files 166	
were concatenated, then assembled and blasted using bowtie2 very-sensitive-local search. Metaphlan 167	
output files were then merged using the merge_metaphlan_tables.py script, which were normalized and 168	
analyzed using Metaphlan and R visualization tools. 169	
SAMP ileitis transmissibility, cohousing and fecal microbiota homogenization. To determine if 170	
the passive exposure of fecal pathogens in a confined space during cage cohousing could alter the expected 171	
morphological mucosal pattern (presence/absence of cobblestone ileitis) of both AKR and SAMP colonies, 3-172	
week-old SAMP and age/gender-matched AKR mice were weaned and subjected to a 24-week period of 173	
cage cohousing. Since our microbiome data indicated that there was a relevant microbiota variability within 174	
the colony, over time, Splenda experiments were conducted 7 days after applying a fecal microbiota 175	
homogenization protocol (IsPreFeH),18, 25 where all mice were exposed to a composite (pool) of feces from 176	
all intended experimental mice, by gavaging 400 µL of fecal suspensions to each mouse.18, 25 177	
Artificial sweetener experiments in mice. To determine the effects of Splenda supplementation on 178	
SAMP ileitis and gut microbiota, we conducted 3 separate experiments with incremental adjustments. In 179	
experiment 1, we added a ‘low dose’ of Splenda (1.08 mg/mL) to the drinking water for 6 weeks and 180	
compared it to ‘plain water’ using only SAMP mice (6/group). Body weight, microbiological culture based 181	
data (feces and spleen) and ileal histological and SM scores were the main assessments. In experiment 2, 182	
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we repeated the same protocol but increased the dose to the maximum recommended by the FDA (3.5 183	
mg/mL), and included AKR mice (6/group). The fecal bacteriome changes were assessed by using 16S 184	
rRNA microbiome, glucose tolerance tests, and a well validated method of biochemical inflammation based 185	
on the enzymatic detection of MPO in the intestinal tissues, ileum and colon.18, 25 Finally, systemic 186	
inflammation was evaluated by serum TNF-α levels (Ready-Set-Go ELISA kit eBioscience, San Diego, CA) 187	
and glycemic responses assessed by glucose tolerance tests. In experiment 3, we repeated protocol 2 but 188	
administered Splenda at a dose that was 10 times higher than the dose used in Experiment 2 (i.e., 35 189	
mg/mL). The main assessments were MPO activity and intestinal inflammation (histology and SM). To 190	
minimize cage-to-cage clustered variability, all animals were housed individually, and all fresh water bottles 191	
were replaced every 48 h to avoid contamination. Irradiated/autoclaved standard diet was offered to all mice 192	
during experimentation to prevent external microbial confounders. We have recently reported the effect of 193	
soiled bedding in the mouse microbiome as a source of ‘cyclical bedding-dependent bias’ in microbiome 194	
research, which could be varied depending on a number of factors, including the number of mice, microbiota 195	
and humidity (Rodriguez-Palacios, 2017 under review). In the present study, we controlled for ‘cyclical bias’ 196	
by i) housing all mice individually, ii) maintaining all cages in HEPA filtered pressurized standard dorms (low 197	
cage humidity), iii) replacing all cages simultaneously weekly and iv) collecting all data (food consumption, 198	
fecal samples, euthanasia) and samples (live and postmortem) for all animals the same day. 199	
Stereomicroscopic 3D-pattern profiling (to determine the presence of SM abnormalities on the mucosal 200	
surface) and histological assessment were conducted on Bouin’s fixed intestinal tissues. Histological 201	
evaluation of inflammation severity was determined by hematoxylin and eosin-stained 5-µm-thick sections 202	
using a semi-quantitative scoring system. A board-certified pathologist determined all scores in a blinded 203	
fashion. The detailed 3D-SMAPgut protocol’s considerations along with the scoring forms and criteria are 204	
validated and described.18 205	
Relative enumeration of fecal bacterial communities using a ‘Parallel Lanes Plating’ method. 206	
Traditionally, the enumeration of total bacteria from feces has been conducted using spread plate methods, 207	
which require up to ten 10-fold serial dilutions to inoculate 100 µL of each dilution in individual agar plates. 26, 208	
27 For feces, which contain up to 8-9 Log10 colony-forming units (CFU) of bacteria per gram, a full 209	
quantitating spectrum requires up to 10 agar plates.  To reduce costs, scientists often plate dilutions 7, 8 and 210	
9 to estimate the fecal CFU counts, leaving more concentrated dilutions (1 to 6) unexamined. Other methods 211	
used for enumeration of mono-strain bacterial suspensions in food science, use 5 µL drops of each 10-fold 212	
serial dilution to be ‘spotted’/incubated on an agar plate. Despite their simplicity, spotted platting only allows 213	
the collection of binary data (presence/absence of growth in each spot) to obtain ‘approximate’ CFU Log10 214	
range counts (most-probable number/dilution), with no capabilities to compare the relative growth or 215	
inhibition potential of co-cultured strains.26 Since we were interested in estimating the relative concentrations 216	
of mouse fecal bacterial communities which may vary in natural abundances, and which would be prohibitive 217	
to examine with spread platting methods in the Splenda experiments,27 we developed a method herein 218	
referred to as ‘Parallel Lanes Platting’ to rapidly estimate total and relative bacterial abundances across 219	
numerous dilutions using a single agar plate. This method allows the plating of 8-to-10 10-fold dilutions for 220	
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the simultaneous enumeration of CFU for bacterial subgroups exhibiting colonies of distinct morphological 221	
appearance, irrespective of their concurrent high or low abundances within the same sample. In brief, the 222	
method uses 10-20 µL of each 10-fold serial fecal-dilutions in PBS, which are placed simultaneously as 223	
drops using a multichannel dispenser on one side of a tilted agar plate (>60-80o angle).  The inclination of 224	
the agar plate makes the drops slide downward over the agar surface creating parallel lanes of spread 225	
solutions of up to 5 cm2 surface area that allows the easy identification and enumeration of distinct bacterial 226	
colonies and inhibitory interactions across all fecal dilutions (0.5 cm x 10 cm; Supplementary Figure 1). 227	
Upon drying and 48h of aerobic and anaerobic incubation at 37oC, single colonies were enumerated relative 228	
to total CFU of cultivable bacteria in the sample. Agars used included Tryptic soy agar (TSA) supplemented 229	
with 5% Sheep Blood (BD, Downers Grove, IL), Luria Brentani (LB, enterobacteria), de Mann Rogose 230	
Sharpe (lactobacilli), meat liver (fastidious anaerobes and sulphite reducers), and plain microbiological agar 231	
supplemented solely with either yeast extract, maltodextrin, or Splenda (at 3.5%). In selected media (TSA), 232	
purified colonies were Sanger sequenced following standard protocols. Specific Helicobacter primers were 233	
also used to semi-quantify Helicobacter spp. in feces and tissue of selected animals using amplicon gel 234	
analysis (5'- B38 GCA TTT GAA ACT GTT ACT CTG; B39 CTG TTT TCA AGC TCC CCG AAG; C97 GCT 235	
ATG ACG GGT ATC C; C98 GAT TTT ACC CCT ACA CCA).28  236	
16S rRNA gene microbiome analysis. Microbiome analyses were conducted at CWRU using Ion 237	
Torrent protocols, which have been validated and described in detail.29, 30 To quantify bacterial changes 238	
associated with the 6-week supplementation of Splenda, we used pure DNA from end-point fecal samples 239	
(day 42-47) to PCR-amplify the V4 region of the 16S rRNA gene in triplicate using primers Forward-S-D-240	
Bact-0564-a-S-15 (5′-AYT GGG YDT AAA GNG) and Reverse-S-D-Bact-0785-b-A-18 (5′-TAC NVG GGT 241	
ATC TAA TCC) as previously reported.30 PCR products were then evaluated by electrophoresis in 2% 242	
agarose gel and purified with the Agencourt AMPure XP system.  PCR amplicons were selected to obtain 243	
400-bp length for library preparation, which were sequenced using Ion Torrent reagents and a benchtop 244	
sequencer at CWRU. Pair ended 2×250 chemistry and fluorescently labeled forward primer 27F (5′-6FAM- 245	
AGA GTTTGATCCTGGCTCAG) with unlabeled reverse primer 355R5′ (5′- GCT GCC TCC CGT AGG AGT) 246	
31 were used to amplify the first two variable regions of 16S rRNA gene as previously described.32, 33 For 247	
sequence analysis, the mothur package of algorithms (v1.32.1)34 and associated dependencies were used. 248	
As we previously reported,30 aligned paired ended reads aligned to Silva 16S rRNA reference database. 249	
Sequences that were >244-bp or <239-bp in length, contained any ambiguous base calls or long runs (>8 250	
bp) of holopolymers or did not align with the correct region were removed. Chimeras were identified using 251	
uchime and eliminated. CatchAll was used to assess species richness, while taxonomy assignment relied on 252	
RDP taxonomy database (http://rdp.cme.msu.edu/index.jsp). Sequences were binned into operational taxon 253	
units (OTUs) at a 3% dissimilarity level. Instead of subsampling for normalization as often performed,30 we 254	
normalized the OTU tables by rescaling the abundances of all samples to the fecal sample having the lowest 255	
total sequence abundance in the study. R software was used to visualize the microbiome profile and 256	
compute univariate and multivariate statistics. Dendrograms were computed using Euclidean distances and 257	
when distinct unsupervised hierarchical clusters were observed, we tested the mouse allocation using 258	
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frequency statistics (Fisher’s exact). In this fashion, we determined whether the allocation of mice to the 259	
microbiome clusters was random or significantly linked to the study variables, especially mouse strain and 260	
treatment (Splenda or plain water).  261	
Quantitative polymerase chain reaction (qPCR) of mucosa-associated bacteria. DNA was 262	
isolated from ileal tissue using the Roche High Pure PCR Template Prep Kit for genomic DNA isolation. 263	
qPCR was performed using 10 ng DNA in all reactions and primers for Eubacteria 35 or six 16S rRNA 264	
specific sequences for Escherichia coli 36, Bacteroides, Lactobacillus/Enterococcus, Eubacterium 265	
rectale/Clostridium coccoides (Erec), Segmented Filamentous Bacteria (SFB), and mouse intestinal 266	
Bacteroides (MIB) 37 in iTaq SYBR Green Supermix with ROX (BioRad) on an ABI prism 7900HT 267	
(ThermoFisher Scientific) using SDS2.4 software. Samples were run in triplicate.  Because there is no proper 268	
widely accepted ‘reference control bacterial population marker’ to normalize qPCR microbiome data, 269	
quantitative strain-specific 16S primer amplicon data were analyzed collectively using the raw qPCR-CT 270	
values as described earlier18 and multivariable statistics to visualize and quantify the overall impact of the AS 271	
supplementation on the mucosa-associated microbial composition in the ileum of mice.  272	
Fluorescent in situ hybridization (FISH). To visualize the localization of bacteria carrying the malX 273	
gene, which encodes for maltodextrin degrading enzymes,14, 38, 39 ileal tissues were fixed in methanol-based 274	
Carnoy’s fixative (60% absolute methanol, 30% glacial acetic acid, 10% chloroform), embedded in paraffin 275	
blocks, and sectioned. Five µm sections were deparaffinized and hybridized with 250 ng E.coli-Cy3 probe 276	
(5’-Cy3-CAT CTT CAC AGC GAG TTC-3’), 500ng MalX-Alexa488 probe (5’Alex488-277	
ACGCGTTTCCTTTCGCAA-Alexa488-3’), and Eubacteria338-Alexa647 probe (5’Alexa647-278	
GCTGCCTCCCGTAGGAGT-3’) or buffer-only controls in 20 mM Tris-HCL, 0.01% SDS, 0.9M NaCl at 46°C 279	
overnight 40. Slides were then rinsed twice with water, incubated 5 min in 20 mM Tris-HCL, 0.9 M NaCl at 280	
46°C, rinsed twice with water, dried 10 min at 46°C and applied with Vectashield containing DAPI (Vector 281	
Labs) and coverslips. Imaging was acquired using a Leica TCS-SP spectral laser scanning confocal 282	
microscope equipped with a Q-Imaging Retiga EXi cooled CCD camera and Image ProPlus Capture and 283	
Analysis software (Media Cybernetics). Image z-stacks were collected every 0.49 µm spanning the full 284	
thickness of cells and exported for image analysis using Image ProPlus Capture and Analysis software 285	
(Media Cybernetics). 286	
Statistical analysis. In all experiments mice were randomized using a systematic approach, and 287	
then convenience, and used optimal analytical and matching strategies to control for confounding bias as are 288	
frequently implemented in interventional and observational studies.41 Further, blinding was enforced in 289	
experimental and analytical stages since Splenda supplementation or Helicobacter status was not obvious to 290	
handlers; non-informative codes were revealed after analysis. Both univariate and multivariate statistical 291	
analyses were conducted independently for each Splenda dosing. Parametric statistics (Student’s t tests 292	
and/or one-way ANOVA) or their nonparametric alternatives were used to compare experimental data (i.e., 293	
body weight, inflammatory scores, MPO activity). Metagenomic and microbiome bacterial abundance data 294	
(OTU taxonomic tables) were log transformed, normalized and processed using R software or STATA. 295	
Multivariate Hotelling's T-squared distribution statistics was used for the comprehensive analysis of bacterial 296	
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qPCR tissue data.  Data was presented as SD or 95% confidence intervals; significance was held at P≤0.05. 297	
P values between 0.05 and 0.1 are also shown when appropriate.  298	
 299	
RESULTS 300	
The gut metagenome of ileitis-prone SAMP mice is rich in families of the phylum Bacteroidetes. 301	
Prior to testing the effects of Splenda, we first examined the gut metagenome profile of the SAMP 302	
‘experimental mouse’ colony compared to the AKR, which have been maintained together in the same 303	
animal CWRU facility for over 10 years.  Because each colony could have selected for their own microbiome, 304	
adapted to their health or diseased intestinal environment through the years, it was important to determine 305	
whether potential microbiome differences (‘shifts/drifts’) could be attributable to the IBD susceptibility 306	
genotype and the progressive SAMP phenotype (mild inflammation in young; severe inflammation in adult). 307	
For this purpose, fecal samples from 6 experimental mice (3 males, 3 females; 6 cages) across 3 different 308	
age groups (7-, 22- and 50-week-old, see experimental design in Figure 1A) were collected, processed, 309	
pooled for DNA extraction and sequenced using metagenome MiSeq Illumina sequencing reagents. We 310	
used pooling to create a composite sample for each age group as a valid screening method to control for 311	
background individual and cage variability, because fecal pooling is a powerful and cost effective approach 312	
to study the microbial phenotype of large animal populations (with pooling of 5-10 individual samples 313	
showing optimal performance).42, 43 At the phylum level, metagenomics revealed a significant increase in the 314	
Bacteroidetes phylum in SAMP mice. At the class level, within the Bacteroidetes phylum, Sphingobacteriia 315	
and Bacteroidia were increased in SAMP compared to AKR mice (Figures 1B-E). Within these 2 classes, 316	
out of 7 possible in the phylum Bacteroidetes, which was the most abundant phylum in the study, it is 317	
remarkable that the most abundant species identified in the phylum belonged to 4 out of 6 possible genera in 318	
the class Bacteroidia (Prevotella, Alisitipes, Parabacteroides, and Bacteroides; Order Bacteroidales). 319	
Collectively, Bacteroidia was most commonly altered in SAMP mice compared to only one genus increased 320	
out of 6 possible in Sphingobacteriia (1/6 vs. 4/6; one-tailed Fisher P=0.045, see species in Figure 1E). This 321	
finding is experimentally relevant to CD, because CD has been associated with tissue Bacteroidetes 322	
enriched dysbiosis (e.g., Bacteroides and Prevotella genera in gut mucosal samples).44  323	
Within the phylum Proteobacteria, analysis at the family level revealed a striking increase of 324	
Helicobacteraceae (C:Epsilonproteobacteria, O:Campylobacterales) in SAMP mice (Figure 1B-E). However, 325	
since Helicobacteraceae (the 6th most abundant family in the study, out of 41) was already abundant in 326	
young SAMP mice (7 weeks of age), the findings suggested that Helicobacteraceae abundance was not due 327	
to the severity of ileitis, which is typically undetected at three weeks of age, but could affect >60% of ileal 328	
mucosa by 55 weeks of age. Because metagenomics is robustly based on the quantification of bacterial 329	
communities using single-copy gene data, results from pooling (n=36) mice strongly indicated, for the first 330	
time, that the SAMP microbiome phenotype is rich in several Bacteriodetes families, and surprisingly 331	
dichotomous and rich in Helicobacteriaceae. Because Helicobacter has been considered both a confounding 332	
factor and a necessary organism in certain B6 mouse models of colitis, but not all,45 it was deemed 333	
necessary to confirm the findings with a new set of samples for individual (not pooled) metagenomics. 334	
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Especially, since Bacteroidales and Helicobacteraceae are known inhabitants of the human intestine with the 335	
potential to become opportunistic pathogens; e.g., Odoribacter splanchnicus (see Figure 1).46, 47 336	
Virome sequencing reveals absence of norovirus in ‘pooled-feces’.  337	
To further investigate the microbiome of the ‘pooled-feces’ experiment in our colony, fecal samples 338	
were also processed and shotgun-sequenced using a Roche 454-sequencing platform to screen for the 339	
presence of DNA and cDNA viral genomes, in addition to Illumina sequencing. Metagenomic examination of 340	
the sequences indicated the absence of norovirus in the pooled samples. Thus far, metagenomic analysis 341	
has indicated the absence of detectable dsDNA viruses in the pooled feces of young SAMP and AKR mice. 342	
PCR for norovirus and novel astroviruses were also negative, although testing of our SPF colony has been 343	
shown to be variably seropositive for norovirus over time. We recently reported a concurrent serological 344	
screening of adult SAMP mice reared under germ-free (GF) conditions, wherein SAMP exhibiting 345	
cobblestone ileitis had no seroconversion to norovirus for up to 62 weeks of age. Thus, serology indicated 346	
that SAMP ileitis occurred independently of norovirus, a virus needed to promote intestinal inflammation in 347	
ATG16L1-gene-dependent models using B6 mice.48, 49 348	
Individual metagenomics illustrate great cage and facility variability of Helicobacter in mice. 349	
To verify that Helicobacteraceae was stably abundant in SAMP mice over time, a second 350	
metagenomic analysis was conducted 8 months after the ‘pooled’ metagenomics evaluation, but testing 351	
individual fecal samples from ‘breeder mice’. Paired male:female mice were sampled as clustered by cage to 352	
validate the reproducibility of our unsupervised metagenome hierarchical analysis used in the pooled 353	
metagenome analyses of ‘experimental mice’. Eighteen active 30 week-old breeders (1 male, 1 non-354	
pregnant female/cage) were tested as representative because they would be the main source of gut 355	
commensal microbes inherited to the offspring ‘experimental mice’ sampled earlier. To properly determine 356	
whether Helicobacteraceae was abnormal in SAMP, B6 breeders were also sampled, along with the original 357	
AKR vs. SAMP colonies (Figure 1A). To ensure compliance on scientific rigor and data reproducibility, 358	
SAMP and AKR mice were also sampled from an alternate colony (in facility B). Unexpectedly, metagenomic 359	
analysis (54.4 million raw reads; 20.9 million high-quality bacterial paired-ended, 79±5% unique) revealed 360	
major variability for Helicobacteraceae across the colonies and facilities, further challenging the relevance of 361	
Helicobacteraceae as causally associated with SAMP ileitis. This time, Helicobacter was absent in 3 cages 362	
of SAMP and B6 mice, but abundant in a cage of AKR in our facility A (Figure 2A), which was opposite to 363	
concurrent findings in alternate facility B. Analysis clearly showed that the ability to sequence Helicobacter in 364	
SPF mice was highly variable and dichotomous (either highly abundant, or absent), likely due to seasonality 365	
or individual cage differences. Given the high variability, no absolute conclusion could be drawn regarding 366	
the potential causal or modulatory role of Helicobacter on SAMP cobblestone ileitis. However, the analysis i) 367	
confirmed that Bacteroides are abundant in adult SAMP mice, and ii) verified the optimal reproducibility of 368	
our metagenomic methods since pairs of breeders always clustered together (as expected within their cage 369	
assignment) using unsupervised clustered analysis (Figure 2A-D).  370	
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The presence of Helicobacteraceae does not alter cobblestone lesion progression in SAMP ileitis  371	
Verifying that SAMP and AKR mice housed in our facility had Helicobacter spp. in their feces at the 372	
time metagenomic results became available, specific 16S-primer amplification of fecal bacterial DNA 373	
confirmed that both mouse lines in facility A harbored the bacterium in their feces, and that SAMP could 374	
have more DNA copy numbers (Figure 2E). Because the initial pooled metagenomic analysis indicated a 375	
strong signature for Helicobacter spp., we then created a new SAMP colony by re-derivation and 376	
colonization with a Helicobacter-negative mouse microbiota at the National Institutes of Health. Following re-377	
derivation, breeding pairs were transported and housed in our facility for phenotype testing. SM analysis of 378	
the small intestines of mice at 30 weeks of age, revealed a persistence of the 3D-cobblestone lesion 379	
architecture in the inflamed ileum, while histological analysis over time of this colony revealed that 380	
Helicobacter was not necessary for the disease to occur or histologically worsen (Figure 2F; the study of 381	
immunophenotyping differences is in progress and will be reported separately).  382	
The SAMP ileitis is not transmissible or preventable during long-term cohabitation with healthy mice 383	
Previous studies using DSS colitic mice and cohousing suggested that acute colitis is ‘transmissible’ 384	
from affected B6 mice to unaffected mice by exposure to their gut microbiota.50 By using cohousing, others 385	
have reported that the microbiota of NOD2 knockout B6 mice transmit colitogenic properties to B6 mice, 386	
primarily via changes in Butyrivibrio, Lachnobacterium spp, and in Bacteroides (above shown to be also 387	
increased in SAMP).51 In contrast, we recently determined that the same NOD2 mutation in SAMP 388	
unexpectedly improved, rather than exacerbated, the cobblestone ileitis (50% better, at 30 weeks old) and 389	
reduced the severity of DSS colitis.52 Furthermore, in contrast, we found no evidence to suggest that the 390	
anti-inflammatory benefit of the mutation was due to a given microbiome profile based on fecal 391	
metatranscriptomic (bacterial gene expression mRNA) and 16S microbiome analyses. Although the concept 392	
of transmissible colitis seemed relevant to the genetics of B6 mice, genomic differences in our SAMP model 393	
and its spontaneous progressive ileitis phenotype21 prompted us to determine whether microbiome exposure 394	
of young, 3-week-old healthy AKR mice during cohousing could protect young 3-week-old SAMP mice from 395	
developing ileitis, and whether disease could be transmissible to AKR in a long-term contact experiment.  396	
The experiment was conducted for 6 months with 14 mice. 3D-SMAPgut analyses showed that the 3D-ileitis 397	
phenotype was not transmissible to AKR mice, and that SAMP ileitis was not prevented during cohabitation 398	
with AKR. Culture analysis (anaerobes and enterobacterial fecal enumeration) indicated that although the 399	
total bacterial load was similar for AKR and SAMP cohoused mice, SAMP favored gut enterobacterial growth 400	
(Supplementary Figure 1).  401	
Together, the aforementioned analyses indicated that SAMP ileitis i) had a Bacteroidetes-rich 402	
microbiome phenotype, ii) had increased likelihood to favor enterobacterial growth, iii) could develop 403	
cobblestone lesions unaffected by the presence of Helicobacter and norovirus in the gut, and iv) was not 404	
transmissible to AKR by long-term cohousing. Crossover experimentation with fecal transplantation from 405	
SAMP into germ-free (GF)-AKR mice, and vice versa, was considered to verify that SAMP ileitis was not 406	
microbiome-transmissible, but the experiment was not possible due to the lack of available GF-AKR mice at 407	
the time. Due to animal welfare concerns (SAMP-AKR mouse fights, with SAMP hierarchical dominance in 408	
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cohousing experiments) we determined that Splenda experiments could not be conducted with adult AKR 409	
and SAMP cohoused mice.  410	
Splenda does not alter the SAMP cobblestone ileitis phenotype, but increases tissue MPO activity 411	
Due to difficulties in cohousing AKR and SAMP mice and in controlling for the observed 412	
metagenome cage variability, we implemented the ‘IsPreFeH’ protocol18, 25 among all animals52 subjected to 413	
the Splenda experiments, which was followed by individual animal housing and Splenda supplementation for 414	
42-47 days. Although low dose supplementation resulted in transient body weight reduction during 415	
supplementation (generalized linear regression, GLM P<0.0001), no changes were significant at higher 416	
doses. In addition, although fecal cultures showed Splenda promotes enterobacterial and maltodextrin-417	
utilizing bacterial growth in SAMP, no evidence of systemic effects was present from culture of spleens, 418	
serum TNF levels, or blood glucose tolerance tests. Comparing to the total number of anaerobes (TSA) and 419	
lactobacilli (MRS agar), the number of enterobacteria (LB) was significantly increased in Splenda 420	
supplemented SAMP mice. No differences were seen at 1, 3, or 14 days after supplementation  (Figure 3A-421	
G). Unexpectedly, SMAPgut and histological analyses of the ileum showed Splenda did not augment the 422	
ileal inflammation scores, the percentage of SM-abnormal mucosa, or the 3D-morphological features of 423	
cobblestone lesions in SAMP mice at any of the three doses tested, and importantly healthy AKR mice did 424	
not developed ileitis or colitis either. In contrast, a well-validated quantitative enzymatic activity assay 425	
showed that the amount of MPO reactivity in the ileum of SAMP mice treated with the Splenda FDA 426	
maximum approved dose (3.5 mg/mL) was 2.7-times higher compared to SAMP mice drinking plain water 427	
(219.1 vs. 81.8 U/g, t-test P=0.022). Controlling for multiple variables, analysis of ileal tissues of SAMP mice 428	
in experiment 3 (high-dose, 35 mg/mL) confirmed that increased increments of MPO activity occurred only in 429	
Splenda-treated SAMP (Two-way ANOVA F2,27=4.08, P=0.055, controlling for significant interaction between 430	
Splenda and organ [colon vs. ileum] P=0.0515). Interestingly, the same doses of Splenda had no effects on 431	
ileal MPO in AKR mice (i.e., exp. 3, Two-way ANOVA F2,21=0.09, P>0.76). The MPO in the colon was lower 432	
compared to ileum (Two-way ANOVAs for AKR and SAMP, P=0.012 and P<0.0001), which was unaltered by 433	
Splenda in both mouse lines (Figure 4A-E). Results suggested that Splenda promoted the increase of 434	
intestinal MPO tissue reactivity (‘biochemical inflammation’) only in the gut wall of mice prone to IBD, without 435	
inducing major (noticeable histologic) microscopic changes associated with active inflammation. This finding 436	
is remarkable considering that subclinical inflammation (i.e., increased MPO and other inflammatory 437	
biomarkers, with no evidence of histological abnormalities) has recently been observed in healthy twins of 438	
monozygotic and dizygotic discordant pairs with IBD compared to healthy non-twin relatives. This further 439	
supports the concept that a combination of genetic and environmental factors predisposes individuals to 440	
biochemical inflammation in IBD patients.53 441	
Splenda promotes gut microbiome dysbiosis and Proteobacteria in SAMP and AKR mice  442	
Differences in fecal bacterial composition were assessed using 16S microbiome analysis (1.42 443	
million V4 16S RNA gene sequences from 20 mice; 70879/samples that passed quality control filters; 444	
99.36% had a Blast hit match in the 16S database). Corroborating the culture findings from SAMP mice 445	
treated with Splenda®, analysis revealed that the most consistent effect that Splenda supplementation had 446	
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on the mouse microbiome was a significantly widespread promotion of bacterial species across the 5 447	
microbial classes identified within the Proteobacteria phylum (Alphaproteobacteria, Betaproteobacteria, 448	
Epsilonproteobacteria, Deltaproteobacteria and Gammaproteobacteria). Comparison of proteobacterial 449	
mean abundances between AKR and SAMP indicates that SAMP were likely to have more Proteobacteria in 450	
control (6/6; one-tail Sign P=0.016, see culture agars from cohouse AKR-SAMP mice in Supplementary 451	
Figure 1e) and Splenda groups (5/6; one-tail Sign P=0.109) (Figure 5A-D). Comparatively, microbiome 452	
analysis also showed that subtle differences exist between AKR and SAMP mice, which clusters them 453	
separately as mouse strains. In addition, Splenda altered the gut microbiome by reducing some other phyla, 454	
while no significant effect was observed in Bacteroidetes or Firmicutes (e.g., lactobacilli and clostridia), which 455	
also clustered the mice according to the dietary impact on their gut microbes (Figure 5A-D).  Culture data 456	
from Splenda-treated SAMP compared to mice drinking water showed Splenda® had no effect on the counts 457	
of lactobacilli (MRS agar), total bacteria (TSA), or anaerobic clostridial species (MRS, TSA and meat liver 458	
agars; GLM of normalized Log10 adjusted P>0.2), while it promoted the remarkable growth of Escherichia 459	
coli in the feces of mice. Of interest, E. coli overgrowth apparently occurred at the expense of displacing, at 460	
least, cultivable Streptococcus-like organisms, which were evident in the feces of mice drinking only water 461	
(Figure 6).  Because several lines of evidence indicated that Splenda promotes MPO tissue reactivity and 462	
the overgrowth of E. coli (Gammaproteobacteria) in intestinal content (i.e., feces), we then used qPCR and 463	
FISH analysis to determine whether ileal tissue from SAMP mice treated with Splenda would have mucosal-464	
associated dysbiosis and increased bacterial infiltration into deep intestinal layers. 465	
Splenda causes distinct ileal tissue microbiota with increased bacterial MalX gene in SAMP mice. 466	
Multivariate quantitative analysis of DNA copy numbers in ileal (full thickness) tissue samples from 467	
SAMP mice using seven specific primers for various bacterial families/species revealed that supplemented 468	
mice had a distinct (‘dysbiotic’) microbiome profile when compared to untreated animals (see enrichment of 469	
Eubacteria, lactobacilli, and the contribution of E. coli illustrated as two-dimensional vectors in Figure 7A). 470	
Although SAMP ileitis has been known to be a highly segmental disease of the small intestine, blinded FISH 471	
analysis of SAMP mice confirmed that the ilea of Splenda-treated SAMP mice had increased numbers and 472	
larger clusters of bacteria within the villi compared to untreated SAMP, and AKR mice. These bacterial 473	
clusters positively hybridized with an E. coli probe and a probe to malX, a gene that encodes a maltodextrin-474	
binding protein of the maltose/maltodextrin metabolism system.54 Of translational value, the presence of 475	
FISH-positive clusters was almost imperceptible in ileitis-resistant AKR mice in both groups, with and without 476	
the sucralose/maltodextrin (Splenda) supplementation (Figure 7B-C). This observation further supports that 477	
sucralose/maltodextrin have a dysbiotic effect in ileitis-prone SAMP mice, but not in healthy AKR mice.  478	
Together, our data indicate that sucralose/maltodextrin (e.g., Splenda) daily supplementation in the 479	
water (for 6 weeks) promotes bacterial dysbiosis with proliferation of Proteobacteria species, including E. 480	
coli, and increased bacterial invasiveness into villi tissue, which may in turn increase the MPO reactivity of 481	
ileal tissues during the course of murine cobblestone ileitis.  482	
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DISCUSSION 483	
CD is a chronic relapsing-remitting IBD with a tendency to develop highly distinctive fecal microbiota 484	
disturbances (dysbiosis) compared to other forms of IBD.55 Characteristically, CD has abundant 485	
Bacteroidetes and reduced presence of Firmicutes.56, 57 A recent meta-analysis of raw sequencing data from 486	
IBD microbiome studies, together with DGGE studies,56, 57 indicated that some CD patients may not have 487	
high abundance of fecal Bacteroidetes, suggesting that either there are two types of CD patients based on 488	
the presence of this phylum, or that there is large data variability. Our own studies support the role of 489	
Bacteroidetes in CD, as we recently discovered Bacteroidetes-enriched intramural cavernous fistulous 490	
lesions in the severely inflamed bowel samples removed from patients that underwent surgery for CD.18 For 491	
the first time, we presented data indicating that the SAMP ileitis phenotype is enriched (and not deficient) in 492	
Bacteroidetes, making this model microbiologically relevant to conduct dietary studies in a Bacteroidetes-rich 493	
context. The metagenome analysis also showed large variability for Helicobacteraceae. Although we 494	
assessed the relevance of this genus experimentally by re-deriving the SAMP mouse colony free of 495	
Helicobacter, it is important to highlight that the re-derivation process is inherently difficult to achieve the 496	
composition of a natural microbial community in which only one organism is absent. Despite this inherent 497	
difficulty, the presence of SAMP ileitis in animals lacking Helicobacter indicates that the role of this genus as 498	
necessary for inducing ileitis in SAMP is minimal. Mono-strain association studies are currently examining 499	
the potentially negligible modulatory effect of this genus on local and systemic immunity in the development 500	
of SAMP ileitis.   501	
Because current microbiome approaches are not quantitative with respect to the net fecal matter 502	
biomass content (e.g., changes in bacteria taxa per gram of feces, and variable limit of detection thresholds 503	
Fig. 5) 58, and because changes in fecal microbiota relative composition may not necessarily imply changes 504	
in the gut wall, we conducted complementary microbial enumeration based methods on fecal samples (Fig. 505	
6) and then qPCR and FISH assays in ileal tissues (Fig. 7), and confirmed that AS supplementation had a 506	
modulatory effect on the mouse microbiome composition of SAMP ileal tissues. Since the effect of Splenda 507	
on MPO activity was exclusive to ileitis-prone SAMP mice, and not in control IBD-free mice, it is reasonable 508	
to assume that CD patients may expect severe worsening of intestinal disease if Splenda was chronically 509	
consumed, even at low concentrations as a regular habit. Similarly, it is also reasonable to highlight that 510	
increased biochemical MPO activity could put CD patients at risk of having exaggerated inflammation if other 511	
circumstances trigger mucosal inflammation, for instance during unexpected food borne bacterial super-512	
infections which will further recruit MPO-containing leukocytes to the intestinal tract.59, 60 Increases in the 513	
relative abundance of Proteobacteria, as identified in our study due to Splenda, have been reported with 514	
various types of intestinal tract diseases in diverse species, including humans. Proteobacteria are a major 515	
phylum of gram-negative bacteria that includes a variety of pathogens common to humans and animals, 516	
including Vibrio, Salmonella, Yersinia, Helicobacter, and Escherichia spp. As a pathological feature, most 517	
Proteobacteria, being Gram-negative, have an outer membrane composed of lipopolysaccharides (LPS), 518	
which are potent triggers of innate immunity, with local and systemic responses, depending on the LPS dose 519	
that is proportional to the rate of bacterial growth.  In this study, we found no clinically- or tumor necrosis 520	
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factor-based evidence of systemic inflammation induced by Splenda. However, we found microbiological and 521	
pathological evidence that Splenda promotes increased, local MPO activity, bacterial penetration of the 522	
intestinal epithelium, and an increased predominance of E. coli. Together, our findings further support the 523	
role of dysbiotic Proteobacteria expansion as a microbial signature of intestinal and epithelial dysfunction.61, 524	
62 525	
The MPO enzyme produced by macrophages evolutionarily plays an essential role in degrading 526	
invading pathogens as one of the earliest lines of defense in innate immunity. However, the induced MPO, in 527	
turn, catalyze reactions that can lead to modifications of proteins and destruction of the extracellular matrix 528	
that may exaggerate inflammation. Therefore, excessive MPO production with Splenda supplementation, 529	
together with the detection of increased bacterial fecal abundance and penetration of E. coli in the gut wall, 530	
could result in the exaggeration of ileitis in CD patients, as suggested by our findings in this study. Since IBD 531	
patients believed that ‘sugary foods’ might be a culprit, contributing to the increased severity of their 532	
symptoms, with epidemiological evidence supporting their clinical deterioration, our AKR-mouse data 533	
indicate that it is reasonable to consider that healthy individuals should not be worried or expect to develop 534	
CD ileitis (or MPO hyper-reactivity) if they consume Splenda. However, IBD-free ‘healthy’ consumers of 535	
sucralose and maltodextrin should be aware that proliferation of Proteobacteria is one of the features 536	
expected with AS-induced dysbiosis, which may functionally 63 modulate other conditions not considered in 537	
our study. Our study only assessed 6 weeks of sweetener supplementation, but a chronic increase of 538	
reactive oxidative stress in inflamed tissues could also carry a higher risk for DNA oxidation and tissue 539	
damage, which have long been considered as predisposing mechanisms for IBD-associated cancer.64-66  540	
It has been almost a century since the introduction of non-caloric AS in our diets, which are 541	
consumed by ~30% of adult Americans. Of interest, some analysis have suggested that there may be a 542	
direct temporal correlation between the incidence of IBD and the amount of AS sold in various countries.67 543	
Although other major shifts occurred in human nutrition, it is also important to highlight that obesity and 544	
diabetes also appear to parallel the increased incidence of IBD.16 Additionally, the term ‘Western diets’ 545	
implies a proven a shift of the gut microbiota that enhances the susceptibility to adherent-invasive E. coli 546	
infections and intestinal inflammation in mice.68 In this study, we report similar findings due solely to the 547	
administration of a minor component of the diet (an artificial sweetener based on a common combination of 548	
sucralose and maltodextrin in retail food markets), suggesting that several dietary habits or additives may 549	
lead to similar microbiota alterations. For instance, diet emulsifiers used as food additives have also been 550	
shown recently to alter the gut microbiota and promote colitis in mice.69 In addition to illustrating the 551	
experimental role of a sucralose-maltodextrin based artificial sweetener (relevant to similar products on the 552	
market) in promoting intestinal dysbiosis and MPO activity, our studies also indicate that it might be possible 553	
to measure Proteobacteria and MPO as simultaneous fecal biomarkers in patients to monitor their gut 554	
(disease/health) adjustment to their diets.   555	
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 556	
Figure 1: Metagenomic analysis of pooled fecal matter reveals an abundance of Bacteroidetes and 557	
Helicobacteraceae in SAMP mice. a) En face stereomicroscopic images of healthy AKR ileal mucosa (top 558	
image) and SAMP cobblestone ileitis (bottom image); schematic illustration of metagenomic sampling design 559	
in SPF facilities (pooled feces in Exp. 1 [summer] vs. individual sampling in Exp. 2 [8 months later, spring]). 560	
b) Multivariable unsupervised hierarchical analysis of metagenomic fecal bacterial abundance from 36 mice 561	
pooled as 6 mice per age group (7, 22, and 55 weeks old). Note that quintessential clustering of AKR and 562	
SAMP samples as separate clades. Arrows illustrate distinct families, ranked by abundance across all 563	
samples. c) Compared to AKR, SAMP metagenome had greater bacterial diversity (Shannon diversity). d) 564	
Boxplots reveal reduction of Firmicutes (Lactobacillaceae and Clostridiales), and expansion of Bacteroidetes 565	
families in SAMP (e.g., Bacteroidaceae, Rickenellaceae, Sphingobacteriaceae). e) Circular diagram of 566	
relative taxonomic metagenomic abundance in phylogenetic tree format highlights significant enrichment of 567	
Helicobacteraceae (Proteobacteria phylum), and 4 of 6 known Bacteroidetes phylum families 568	
(Bacteroidaceae, Rickenellaceae, Porphyromonadaceae, and Prevotellaceae) in SAMP mice (one tailed- 569	
Fisher’s exact P=0.046).   570	
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 571	
Figure 2. Metagenomic analysis reveals Helicobacter variability with minimal effect on SAMP ileitis.  572	
a) Individual fecal metagenomic analysis of breeder mice was performed 8 months after the previously 573	
pooled-fecal sampling experiment, demonstrating bacterial profiles with reproducibly cluster within pairs of 574	
breeders for each individual cage. Squares highlight absence of Helicobacteraceae in Helicobacteraceae-575	
negative SAMP colony. When present, Helicobacteraceae was highly abundant in the feces of positive mice. 576	
b) Boxplots, showing averages for each cage, reveal high abundance of Bacteroidaceae in SAMP mice 577	
(comparing to exp. 1 in Figure 1d). c) The abundance of other Bacteroidetes is shown by boxplots. d) 578	
Compared to AKR and B6 mice, SAMP had a significantly higher level of Enterobacteracea (a family that 579	
contains Escherichia coli). Notice marked abundance dichotomous variability of Helicobacteraceae in mice. 580	
e) Gel electrophoresis of PCR amplified target regions of Helicobacter spp. within the 16S rRNA gene from 581	
fecal DNA of random mice form our SAMP and AKR colony, 4 months after the individual fecal metagenomic 582	
experiment. Notice high band intensity in SAMP (asterisks). Universal and PCR-specific primers were used 583	
to generate full or partial gene amplicons (1500 or 400 bp). f) Histological inflammation scores of distal ileal 584	
from re-derived Helicobacter-negative SAMP compared to that of the SAMP colony show no differences. g) 585	
Representative snapshot of videostereomicroscopy shows unchanged morphological appearance of ileal 586	
mucosal surface in Helicobacter-negative SAMP mice; scale: 500um.  587	
	 18 
 588	
Figure 3: Effects of Splenda on body weight, fecal bacteria and glucose tolerance in SAMP mice. 589	
a) Mean body weight change in 12 SAMP mice (individually caged, 7 days of adaptation, over 42 days of 590	
supplementation of drinking water with and without low dose Splenda).  b) Daily group average of body 591	
weight change over time. Low Splenda dose. c) Bacterial enumeration from feces using standard Luria 592	
Bertani (LB) agar (used for enterobacteria) and in-house ‘Maltodextrin agar’.  Notice maltodextrin agar 593	
yielded an increasing bacterial count trend towards the end of study in Splenda group (GLM P>0.05; relative 594	
to centered log transformed data for LB agar). Supplementary Fig. 1 illustrates other in-house agars, yeast 595	
extract agar and Splenda® agar yielding similar trends, compared to LB agar. d) Total number of anaerobes 596	
(TSA), lactobacilli (MRS agar), and enterobacteria (LB) after 42d of Splenda supplementation in SAMP mice 597	
(Unpaired t- test, n=6/group). e) Total number of enterobacteria in spleen suggests Splenda had no systemic 598	
bacteremic effect. f) Glucose tolerance test on day 40 with animals with Splenda supplementation in 599	
experiment 2 (high FDA approved dose). Notice lack of significant effect across experimental mice. g) 600	
Glucose tolerance test curves illustrated as mean±SD. Univariate analysis across time points showed no 601	
differences due to Splenda. AUC, area under the curve, (n=6 mice/group).    602	
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 603	
Figure 4: Splenda has no effect on 3D-SM or histological scores, but promotes tissue MPO activity in 604	
mice with ileitis.  605	
a) En face stereomicroscopic images of AKR and SAMP ileal mucosa after 47 days of supplementation of 606	
Splenda® at maximum FDA approved dose (Experiment 2, medium dose, AKR vs SAMP mice, n=6/group, 607	
supplementation started at 25.2±2.4 weeks of age). Notice similar 3D stereoenterotype for SAMP 608	
cobblestone ileitis and the healthy mucosa in AKR mice. b) Cumulative 3D-SMAPgut scores on mucosal 609	
surface morphology for colon (corrugation score/cm) and ileum (percentage of abnormal mucosa). Despite 610	
the positive trend (upward lines connecting means), there was no statistical difference between groups in all 611	
three Splenda experiments, irrespective of dose. c) Average size for average cobblestone for each cm of the 612	
distal ileum. d) MPO activity from colon and ileum tissue at the end of experiment. Notice increased MPO 613	
occurred only in mice with ileitis. Inset: Example of MPO activity for three tissues with different MPO 614	
reactivities. Notice the reproducibility among triplicates (Supplementary Table 1).  e) Histological scores of 615	




Figure 5: Splenda promotes gut dysbiosis characterized by enrichment of Proteobacteria in mice.  619	
a) Phylum analysis. 16S rRNA gene copy microbiome abundance normalized and presented as an 620	
unsupervised clustered hierarchical heat map which illustrates a significant effect attributable to Splenda 621	
(increase Proteobacteria, and reduction of other phyla including Chloroflexi) (P=0.02). Note high relative 622	
abundance of Bacteroidetes with respect to Firmicutes. Abbreviations, mouse A, AKR/J and S, SAMP; diet 623	
S, Splenda; C, control water. b) Class analysis. Notice that when present several proteobacterial classes 624	
contribute to microbiome separation between SAMP and AKR (P=0.07). Notice highly abundant Bacteroidia, 625	
Bacilli and Clostridia cluster at top of panel. c) Boxplot illustrates the effect of Splenda® on phylum 626	
Proteobacteria, compared to Firmicutes. Lines connecting normalized averages indicate positive trends.  d) 627	
Boxplot illustrates high Bacteroidetes abundance and the comparative reduction of other phyla in Splenda® 628	
treated mice. e) Bacterial abundance across five of the five Proteobacteria classes detected in the study. 629	
Sign binomial statistics of means in Log10 scale suggests that Splenda promotes a positive effect (including 630	
panel c; 10/12 were positive, 2/12 were negative, one-tail sign P=0.019).   631	
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 632	
Figure 6: Splenda promotes the replacement of Streptococcus spp. with E. coli in the intestinal tract 633	
of SAMP mice. 634	
a) Photograph of BHI agar plates supplemented with 5% sheep defibrinated blood inoculated with 10-fold 635	
serial dilutions of feces from SAMP mice using a Parallel minidrop slide and lanes method herein developed 636	
for tracking and relative enumeration of complex bacterial communities (Supplementary Fig 1). Mice were 637	
caged individually and exposed to a composite of bedding and feces (IsPreFeH) prior to receiving Splenda at 638	
a low dose (1.5 mg/mL) or water for 42 days. Representative colonies comprising all possible morphologies 639	
in each agar plate were selected for purification and Sanger sequencing for speciation (from high dilutions, 640	
green labels; and low dilutions, pink or red labels). Notice the colony morphology (large, thick, spreading) of 641	
4/6 mice in Splenda is different from that of 4/6 control mice (whitish, smaller). b) Sanger sequence 642	
chromatograph. Single colony PCR revealed Lactobacillus gasseri (umbonate, brown) as the most common 643	
abundant bacteria in mice, unaffected by Splenda supplementation (see panels below). c) Phylogenetic 644	
analysis of 16S rRNA paired ended consensus sequences revealed that the whitish colonies in Control 645	
(water) group were closely related to Streptococcus spp., while bacteria in Splenda mice were E. coli.  d-e) 646	
Close up of colony morphologies on BHI agar after 5 days of aerobic incubation. Notice ‘parallel lanes 647	
method’ of two mice representing each the Splenda and control groups. Negative numbers indicate 10-fold 648	
dilution factor.  649	
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 650	
Figure 7: Bacterial qPCR and FISH staining of ileal tissue illustrates distinct microbiota and 651	
increased invasive malX+ bacteria (E. coli) in Splenda-supplemented SAMP but not AKR mice.   652	
a) Multivariate analysis of DNA qPCR data from ileum tissues of SAMP mice after 42 days of 653	
supplementation. Notice the display of mice (points) and the vector influence of the variables (arrows) on the 654	
overall matrix data variability (D1 and D2) for the E. coli and Erec primers, and for all the seven primer sets 655	
used in this study. Hotelling's T-test p values are in parenthesis. Notice the separation of the two clusters 656	
(water, Splenda).  b) Ileal sections from SAMP mice supplemented with 3.5% Splenda® for 42 days 657	
(Splenda) or non-treated control mice (Water) were hybridized with probes to Eubacteria (purple), E. coli 658	
(red), and malX (maldodextrin, green), a component of the maltose/maltodextrin metabolism system. Cell 659	
nuclei are visualized with DAPI (blue). Images shown are representative of analyses performed in 5 mice per 660	
group. Notice the presence of E. coli in both the epithelial layer and the sub-epithelial lamina propria tissue 661	
(villi), and the large bacterial clusters in the lamina propria of SAMP mice on the Splenda panels. c) 662	
Percentage of area that stained positive for the malX gene probe (pixels, malX+ area/total tissue area*100). 663	
Unpaired t–test statistics. A minimum of 4 fields were analyzed/sample using ImageProPlus v7 software 664	
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